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ABSTRACT
Using a murine model, topical application of gluco-
corticoid ([GC], 50μg diflucortolone valerate in
ethanol) on a sensitized site (flank skin) for 7 times 
before and 2 times after sensitization on alternate 
days, augmented expression of contact sensitivity reac-
tions on the challenged site (ear skin). This augmenta-
tion was due to the systemic effect of percutaneously 
absorbed GC, because topical GC also augmented 
the skin reaction in mice that had been sensitized on a 
separate site from that of the GC application. In con-
trast, topical application of GC inhibited the contact 
sensitivity skin reaction when applied on the chal-
lenged sites. Intraperitoneal injection of the same dose 
of GC also failed to augment the skin reactions. 
Glucocorticoid augmented the contact sensitivity skin 
reactions and these persisted for 96h after the con-
trol skin reactions subsided. Early phase (1-6h) skin 
reactions were also induced or augmented when 
dinitrofluorobenzene or trinitrochlorobenzene but not 
oxazolone were used as the sensitizer; GC also aug-
mented the non-specific reactions to croton oil or to 
suboptimal concentration of hapten in normal mice. 
The numbers of Langerhans cells (LC) were reduced in 
both the GC-application and challenged sites. Hap-
tenated LC from GC-treated skin showed a rather 
weak sensitizing ability, which was not statistically sig-
nificant. Transfer of lymph node cells and/or spleen 
cells or serum from GC-pre-treated mice failed to 
induce a contact sensitivity reaction in normal recipient 
mice. These results suggest that topical GC might aug-
ment cutaneous inflammation through a possible 
modulation of local cytokine production, regardless 
of the number of LC or the presence of sensitized 
lymphocytes.
Key words: atopic dermatitis, contact sensitivity, 
Langerhans cell, steroid, Thl and Th2 cells.
INTRODUCTION
In the past decade, new types of skin manifestations have 
been recognized in patients with atopic dermatitis (AD), 
especially in Japan.1 These include acute onset of facial 
and/or generalized swelling of the skin followed by ooz-
ing eczematous change with occasional superficial bac-
terial infection (rubor of the skin), persistent erythema of 
the face (atopic red face) and reticular poikilodermic pig-
mentation on the neck (dirty neck).2 They are frequently 
observed in adult patients with AD after long-term use of
steroid ointment and termed adult type-AD. The first con-
dition is thought to be induced by the rebound effect of 
topical steroid ointment and the latter two manifestations 
by the direct or indirect effect of topical steroid.1 To clarify 
whether topical glucocorticoid (GC) modulates cuta-
neous inflammatory reactions, in addition to its known 
anti-inflammatory effect, a murine model was used to 
examine the effect of long-term application of topical GC 
on several kinds of inflammatory responses such as clas-
sical contact sensitivity reactions, or croton oil induced-
irritant reaction. The nature and etiology of AD are still
controversial and no definite pathomechanisms for the 
induction of skin lesions in AD are yet available. 
Consideration of the clinical features of AD revealed that 
some of them showed resistance to topical GC and were 
often exacerbated by application of GC, so it is likely that 
long-term topical use of GC may modulate the immune 
function in the skin.
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METHODS
Animals
BALB/c, and C3H (female, 8-weeks-old), were pur-
chased from Shizuoka Agriculture Co-op. (Shizuoka, 
Japan). They were fed in the laboratory until the study 
began.
Chemicals
Dinitrofluorobenzene (DNFB), dinitrochlorobenzene 
(DNCB), trinitrochlorobenzene (TNCB) and croton oil 
were purchased from Nakarai Chemicals Co. Ltd (Kyoto, 
Japan). Oxazolone was purchased from Aldrich 
Chemical (Milwaukee, WI, USA). FITC-labeled anti-
mouse Ia antibody was purchased from Cosmo Bio Co. 
Ltd. Diflucortolone valerate (1mg/mL), prednisolone 
valerateacetate (3mg/mL), triamcinolone acetonide 
(1mg/mL) were obtained from the respective pharma-
ceutical companies.
Induction of skin reaction
Fifty milliliters of each GC solution in each of the solvent 
or diluted in ethanol was applied 9 times on alternate 
days to the flank skin of mice. On day 12 when the mice 
received the 7th application of GC, each mouse was sen-
sitized with haptens (50mL of 0.5% DNFB, 5% TNCB, or 
3% oxazolone in acetone olive oil 4:1) on eitherthe same 
site as the GC (flank) or a different site (back). On day 
17, one day after the last GC application, each mouse 
was challenged with each hapten (0.15% DNFB, 0.8% 
TNCB, 0.5% oxazolone in acetone olive oil 4:1 solution).
After the challenge test, the increase in ear thickness was 
measured with a micrometer. In the croton oil system, the 
mice received 20mL of 0.5% croton oil on the right 
pinna, and the subsequent increase in ear thickness was 
measured. In some experiments (Fig. 1), mice received 
diflucortolone valerate treatment 4 times on the sensitized 
site on alternate days and were sensitized on day 4 when 
they received the 3rd application of diflucortolone valer-
ate. The mice were then challenged on day 7, 1 day after 
the last GC application. The local effect of GC applica-
tion on the challenged site was studied by applying diflu-
cortolone valerate to the challenged site on day -2, day 
0, day 2 and day 4. Mice were sensitized with 0.5% 
DNFB on the flank skin on day 0 and skin tested with 
0.15% DNFB on day 5 (1 day after the 4th diflucortolone 
valerate application).
Induction of contact sensitivity 
Epidermal cells were obtained from a normal female 
BALB/c mouse (8-weeks-old). Procedures for isolating 
epidermal cells are described in a previous report.3 
Briefly, the mouse's ear was cut off and thoroughly rinsed 
in 70% ethanol. The separated pinna were then washed 
in phosphate-buffered saline, pH 7.4 without Ca2+ or 
Mg2+ (Dulbecco's PBS; Nissui Co. Ltd, Tokyo, Japan), cut 
into 3-4mm2 pieces and then transferred dermal side
down into a petri dish. After 1h incubation at 37℃ in
0.5% trypsin (Difco, Detroit, MI, USA) /PBS solution, epi-
dermal sheets were peeled off from the dermis using fine 
forceps and placed in 'complete medium' (RPMI 1640 
containing 10% heat-inactivated fetal calf serum, 
2mmol/L L-glutamine, 50mg/mL gentamicin, 100 
mg/mL penicillin, 100mg/mL streptomycin, 2.5ng/mL 
fungisone) supplemented with 0.0025% DNase I (Sigma, 
St Louis, MO, USA). After 20-30min, at room tempera-
ture, the sheets were vigorously stirred with the plunger of 
a plastic syringe. After passage through a sterile nylon 
gauze sieve, the resulting cell suspension was collected in
50mL tubes. The viability routinely ranged between 80 
and 90%, as determined by the trypan blue dye exclusion 
test. Single cell suspensions of epidermal cells were 
obtained as described and incubated in 10mmol/L
TNBS in PBS for 20min at 37℃. After washing with PBS
3 times, the cells were incubated in RPMI 1640 with or 
without various concentrations of antibodies for 2h at
37℃. After incubation, 2×105 cells were injected into
foot pads (105/foot pad). After 7 days, the mice were 
challenged with 0.8% TNCB in acetone olive oil (4:1).
Cell transfer
Lymph node cells or spleen cells were obtained from the 
mice 1 day after the challenge test. The mice had been 
GC-pretreated 9 times and sensitized with 0.5% DNFB 6 
days before death, as described earlier. Cell transfer was
investigated by giving 5×107 cells intravenously to naive
mice and then skin testing them after 1h with 0.15% 
DNFB, as described earlier. Cells from mice that had only 
been sensitized were used as the control. In addition, 0.5 
mL of serum from the same GC-pretreated and sensitized 
was also given intravenously to normal recipients to clar-
ify the possible transfer of the contact sensitivity reaction.
Immunohistochemical analysis 
Biopsied specimens from the skin-tested sites, the GC-
pretreated sites and from normal skin were frozen at
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-80℃ until use. A 4mm section was covered with vari-
ous antibodies for the analysis of infiltrating cells. After
incubation at 37℃ for 30min, the sections were washed
with PBS, pH 7.4, and covered with peroxidase-labeled 
anti-mouse or anti-rat Ig antibodies. After 30min of incu-
bation, they were washed and developed with diamino-
benzidine. FITC-labeled anti-la antibody was used to 
identify Langerhans cells (LC) of GC-pretreated or normal 
skin. For this purpose, epidermal sheets were obtained 
from trypsine-treated skin. The number of cells/mm2 in 
three randomly selected fields were counted. Results were
expressed as mean±SE. Mast cells and eosinophils were
identified by Giemsa or toluidine blue stain.
Statistical analysis 
Statistical analysis was performed by Student's t-test.
RESULTS 
Glucocorticoid augments the contact sensitivity 
reaction
To evaluate the effect of topical GC on the cutaneous 
inflammatory response, we applied GC on skin before 
and after contact sensitization, which seems to be the 
equivalent of the clinical state of AD. Sensitization and 
response to various allergens might occur in the patient's 
skin with chronic dermatitis and longstanding use of topi-
cal steroid might modulate these reactions. As is shown in
Fig. 1 a, 9 pplications of 0.1% diflucortolone (7 applica-
tions before and 2 applications after sensitization) on 
sensitized site cl arly augmented DNFB specific contact 
sensitivity reaction in BALB/c mice. Similar results were 
btained when C3H mice were used (data not shown). 
Four applications of GC showed a rather reduced aug-
Fig.1 Augmentation of contact sensitivity skin reaction by glu-
cocorticoid (GC).
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mentative effect compared with 9 applications. 
Application of GC twice after sensitization still showed aa 
augmentative effect. Vehicle control (ethanol) did not 
show any modulatory activity (Fig. 1a). As shown in
Fig. 2 GC application on challenged site inhibited contact 
sensitivity reaction. Diflucortolone valerate was applied on the 
challenged site on day -2, day 0, day 2 and day 4. Mice were 
sensitized with 0.5% DNFB on the flank skin on day 0 and skin 
tested with 0.15% DNFB on day 5 (one day after 4th diflu-
cortolone valerate application).
Fig. 1 b, sensitization on non-GC-treated skin (GC 
applied on flank skin and DNFB applied on back skin) 
showed a similar effect. In contrast to the epicutaneous 
application of GC, no augmentative effect was observed 
when the same doses of GC were applied intraperi-
toneally (Fig. 1 c).
Glucocorticoid application on the challenged 
site inhibited the contact sensitivity reaction
It is generally accepted that GC down-regulates the con-
tact sensitivity reaction through reduction of the number 
of epidermal LC.4-6 Therefore we applied the GC to the 
challenged site on the right pinna twice before and once 
after sensitization. As demonstrated in Fig. 2, four treat-
ments at the challenged site with GC clearly inhibited the 
contact sensitivity reaction. The numbers of LC were 
reduced in both the GC-application site (before/ after
GC application 641±65/246±11) and the challenged
si e (before/after GC application 806±52/101±23).
Augmentation of GC-induced contact 
sensitivity differs among haptens
We used several haptens to induce a contact sensitivity 
reaction. As is shown in Fig. 3 both early (1 and 6 h after 
the challenge test) and late (72 and 96 h after the chal-
Fig. 3 Augmentation of GC-induced contact sensitivity differs among haptens. GC-treated mice were sensitized with (a) DNFB
(b) oxazolone or (c) trinitrochlorobenzene (TNCB).
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Fig. 4 (a) Effect of GC pretreatment on non-specific skin reactions induced by croton oil or (b, c) suboptimal concentrations of DNFB. 
Croton oil (0.5%) or various concentrations of DNFB was applied to the right pinna of GC-pretreated mice (pretreated on the flank 
skin) for the challenge test. Diflucortolone valerate (0.1%) or ethanol was applied to the flank skin 9 times on alternate day (7 appli-
cations before and 2 applications after sensitization). Mice were sensitized with 0.5% DNFB on day 12 (7th application of diflucor-
tolone valerate) on the same site of flank skin where they had received 0.1% diflucortolone 7 times; 0.15% or 0.015% of DNFB 
(suboptimal concentration) or 0.3% DNFB (supraoptimal concentration) were applied to the challenge site on day 17. In the case of 
the croton oil system, mice received only 0.1% diflucortolone 9 times and on day 17 they were challenged with croton oil on the right
pinna for the induction of a non-specific skin reaction.
lenge test) cutaneous reactions were augmented or 
induced when DNFB or TNCB were used for sensitization, 
while only the late cutaneous reaction was augmented 
when oxazolone was used as the sensitizer. In addition 
to the sensitizers, non-specific reactions induced by 
croton oil (Fig. 4a) or a suboptimal concentration of 
DNFB ((0.3%) (Fig. 4b)) were also augmented by GC 
when it was applied at remote sites before elicitation of 
skin reactions.
Dose response and strength of the GC effect 
on the contact sensitivity reaction
We also analyzed the dose response and strength of the 
GC effect on the contact sensitivity reaction. As shown in 
Fig. 5a, higher doses of GC showed a much stronger 
augmentative effect. The strength of GC also showed a 
similar result; diflucortolone valerate (very strong potency) 
showed the highest augmentative effect in contrast to 
prednisolone valerate acetate (strong potency) ortriamci-
nolone acetonide (medium potency) (Fig. 5b).
Inducti n of the contact sensitivity reaction by 
haptenated epidermal cells
As described earlier, the number of LC reduced after top-
ical application of GC. Paradoxically, the contact sensi-
tivity reaction was augmented by GC pre-treatment 
although local LC were reduced in number at the sensi-
tized site. To clarify the sensitizing activity of GC-treated 
LC, we sensitized mice by haptenated epidermal cells 
from GC-treated or ethanol-treated skin. As shown in 
Fig. 6, an early reaction was induced by haptenated epi-
dermal cells from GC pre-treated flank skin, while the 
24-hour reaction was slightly weak compared to that of 
ethanol pretreated flank skin. No augmentative effect 
was observed when a large dose of epidermal cells was 
used for sensitization.
Failure of transfer of contact sensitivity by 
lymph node cells from GC-pretreated mice
To clarify which cells are responsible for the augmenta-
tion of the contact sensitivity reaction, we performed a 
cell transfer experiment using draining lymph node cells
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Fig. 5 Dose response and strength of GC on contact sensitivity
reaction.
from mice pre-treated with GC. As shown in Fig. 7, no 
significant response was induced by lymph node cells 
from mice pretreated with GC in contrast to lymph node 
cells from ethanol-treated mice. A similar result was 
obtained when spleen cells were used for cell transfer. In 
addition, as is well known, the draining lymph node cells 
from mice pre-treated with GC were small and atrophic. 
The number of recovered cells reduced to 10-20% those 
in vehicle-treated mice.
Fig. 6 Induction of contact sensitivity reaction by GC pre-
treated- and haptenated-epidermal cells.
Fig. 7 Failure of transfer of contact sensitivity by lymph node
cells from GC-pretreated mice. Lymph node cells (5×107)
obtained from draining lymph nodes (LN) of GC-pretreated and
DNFB-sensitized mice 24h after a skin test were transferred to
normal recipient mice (see Fig. 1a). After cell transfer, each
mouse was skin tested with DNFB.
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Fig. 8 Histopathological findings of augmented contact sensi-
tivity skin reaction by GC pretreatment.
Histopathological findings of the augmented 
contact sensitivity skin reaction
Figure 8a shows the contact sensitivity skin reaction aug-
mented by GC pretreatment. Marked edematous change 
of the dermis and cellular infiltration were observed, 
which contrasted with the moderate inflammatory skin 
reaction in vehicle-treated mice (Fig. 8b).
DISCUSSION
In the past decade, new types of skin manifestations have 
been recognized in AD, especially in Japan. They are 
frequently observed in adult patients with AD that has 
developed after long-term use of steroid ointment and 
are termed adult-type AD. In addition to AD,7 steroid-
resistant or steroid-exacerbated asthma have been 
reported.8,9 Local cytokine dysregulation has been dem-
onstrated in these patients using in situ hybridization tech-
niques.10 To clarify whether topical GC modulates the 
cutaneous inflammatory reactions, in addition to its 
known anti-inflammatory effect, we examined the effect 
of long-term application of topical GC on several kinds 
of inflammatory responses induced in a murine model. 
 Clinically, AD patients are usually exposed to various 
kinds of foreign allergens and sensitization and elicitation 
occur at the same skin site. Therefore topical steroid 
might act on both the afferent and efferent phases of the 
contact sensitivity reaction induced in AD patients, which 
differs from the experimental system we used.
 It was clearly demonstrated that epicutaneous applica-
tion but not intraperitoneal application of GC on several 
strains of mice augmented the contact sensitivity reac-
tions in a dose- and strength-dependent fashion. This 
augmentative effect contradicts the known anti-inflam-
matory activity of GC11 and might possibly be indepen-
dent from the LC, which is a potent antigen-presenting 
cell in contact sensitivity reactions.12 The number of LC 
was dramatically reduced after GC application, similar to
previous reports,4-6 and we failed to induce an aug-
mented cutaneous reaction by using GC-pretreated LC 
as antigen-presenting cells. Sensitization of the mice at a 
site separate from that of GC application also aug-
mented the cutaneous reaction. Therefore, at present, the 
precise mechanism is not clear; epicutaneously applied 
GC might affect the cutaneous immune system without 
affecting LC function.
 Failure of cell transfer of the contact sensitivity reaction 
using draining lymph node cells also suggests that the 
local cutaneous immunity might be modulated by GC. 
This includes inhibition of the production of immunosup-
pressing cytokine (IL10, TGF-β or IL 1 ra) or potentiation
of the production of inflammatory cytokines such as TNF-
a or IL 1. Recent reports suggest that low dose GC aug-
ments the production of migration inhibitory factor both 
in vitro and in vivo.13
  In our experimental system, GC augmented both irri-
tant and allergic cutaneous reactions. Therefore, it might 
be speculated that GC modulates the anti-inflammatory 
function present in local cutaneous tissue. Interestingly, 
the early reaction was augmented by GC in mice sensi-
tized by DNFB and TNCB but not by oxazolone. This 
reaction persisted and augmented responses were ob-
served with all haptens. This augmented late response is 
similar to the anti-IL 10-treated contact sensitivity 
response reported by Ferguson et al.14-15 Therefore, IL 100 
production might be down-regulated by GC. In support 
of this possibility, we have demonstrated that the local
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application of ILl 0 prevented the augmentative effect of 
GC on the contact sensitivity reaction (unpubl. data). 
Involvement of other candidates (i.e. IL] ra or ILl 3) is cur-
rently under investigation.
 The appearance of an early cutaneous response might 
suggest that GC induces Th2 type helper T cells in addi-
tion to Th 1 helper T cells when DNFB or TNCB were used 
as haptens; however, no Th2 response was observed 
when oxazolone was used. These possibilities are also 
being currently investigated by reverse transcriptase-
polymerase chain reaction analysis of the cytokine pat-
terns of draining lymph nodes and the cutaneous chal-
lenge site (unpubl. data). An alternative mechanism to 
explain our finding is the possible induction of CD8+ T
cells, which mediate the contact sensitivity reaction in the 
absence of Class II positive antigen presenting cells. This 
phenomenon has been reported recently in class II 
knockout mice.16"" In addition, CD8+ T helper type 2 
cells have been reported to play an important role in var-
ious infectious diseases.'$ However, the role of antigen-
presenting cells in the induction of CD8+ T cell-mediated 
contact sensitivity reactions has not been clarified.'b-" 
F4/80+ dermal cells19 or dermal dendritic cells20 might be
other candidates for the antigen-presenting cells in the 
contact sensitivity reaction induced in GC pre-treated 
mice. Unfortunately, in our experimental system, we 
could not examine the effect of anti-CD8 antibody on the 
eliciting of contact sensitivity because of the failure of the 
cell transfer experiment. Systemic administration of anti-
CD8 antibody should be examined in future work. 
However, immunohistochemical analysis suggests that 
the major population of infiltrating cells are CD4+ cells in 
this GC induced-augmented skin lesion (unpubl. data).
 The discrepancy of the GC effect on the murine con-
tact sensitivity response depending on the route of 
administration is not fully understood at present. One 
possibility is that the dose of steroid determines the sup-
pression (high dose) or augmentation (low dose) of the 
immune response, as suggested by Dhabhar et a!.21 To 
clarify this point, the concentration of plasma cortisol 
should be measured after intraperitoneal or epicuta-
neous application of steroid. Another possibility is that 
epicutaneous application of GC for a relatively long 
period might augment the local production of several
kinds of cytokines by keratinocytes. In contrast, intraperi-
toneally applied GC could be rapidly absorbed and 
metabolized without affecting keratinocytes. Preliminary 
data suggests that a low concentration of steroid aug-
mented the production of several cytokines such as ILIa,
IL6 and TNF-a by keratinocytes(unpubl. data). Finally,
this observation might suggest that immunosuppressants 
modulate the immune response under certain circum-
stances, as first demonstrated by Turk et al. who reported 
that cyclophosphamide augmented the delayed hyper-
sensitivity reaction in experimental animals.22 A cell trans-
fer experiment should be performed for analysis of the 
presence or absence of the suppressor B cell described by 
Turk et al.
 More recently, a similar observation was reported by 
Grabbe et a!.23 They applied GC on the challenged site 
of sensitized mice and observed an increased skin reac-
tion with reduced LC. They reported that intraperitoneal 
application of GC also augmented the skin reactions and 
speculated that the increased expression of B7-2 might 
be responsible for the augmentation of the skin reaction. 
These contradictory findings need to be clarified.
 Finally, Kitagaki et a!.24 and Nagai et a!.25 reported that 
repeated applications of hapten induced an augmented 
delayed skin reaction and the appearance of an early 
skin reaction that was similar to late phase reactions. 
These observations might explain the exacerbation of skin 
lesions in AD, other than GC effect on the immune system 
observed in the present study.
In conclusion, refractory AD after extended use of topi-
cal corticosteroid might be one of the unexpected modu-
lators of the cutaneous immune response.
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